A question for consideration, OK, Immutep is at the forefront of lag-3 research...
What is to stop Immutep becoming a commercial entity solely aimed at satisfying big pharmas
research requirements in combination therapies in immuno-oncology sector re lag-3 gene....
Any particular research aimed at different indications etc....
Lag-3 IP remains in immutep hands and big pharma commission trials with the funding/payment
to be negotiated?
I could go on and on but I'm sure you get my drift...
Lag-3 Research Operative
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $240.1K | 720.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 111553 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 16656 | 3 |
View Market Depth
| Last trade - 11.09am 30/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |